Nikpour Abolfazl, Khalilian Alireza, Maleki Iradj, Mohsenipouya Hossein, Yazdani Charati Jamshid
Student Research Committee, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Gastroenterol Hepatol Bed Bench. 2019 Fall;12(4):315-321.
Survey of the survival levels of gastric cancer and its effective causes.
The survival of gastric cancer because of the advances in this type of cancer cures has been increased during the last decades.
643 patients evolved by gastric cancer referred to Imam Khomeini hospital of Sari (2007- 2013) were studied. According to this method, the numbers of 74 patients were neglected because of defective data, and the number of 569 patients went under study. The level of survival was determined by use of Kaplan Meier, so to determine the causes affecting on the patients' survival, the univariate analysis of Log-rank test was used.
Regarding the follow up of these patients during 2013 Nov-Dec the one, 2, 3, 4 and 5 years of survival of these patients were estimated equal to 0.77, 0.65, 0.52, 0.44, 0.27 percent and the survival median equal to 19 months, so survival means equal to 24.49 months. Based on the ranked logarithm test and FDR method some variables like stage (p<0.001) Radiotherapy (p<0.005) and undergo Surgery before Adjuvant chemotherapy (p<0.001) were determined as the effective factors on the survival probability.
The life length of the patients under this article in comparison with developed countries is shallow that might be because of late reference or delayed diagnosis and the shortness of cure facilities. In this way, some materials like soon diagnosis and screen methods could be effective on the increase in patients' survival.
调查胃癌的生存水平及其有效成因。
由于这类癌症治疗方法的进步，胃癌患者的生存率在过去几十年有所提高。
对转诊至萨里伊玛目霍梅尼医院（2007 - 2013年）的643例胃癌患者进行研究。按照此方法，因数据缺陷排除74例患者，对569例患者进行研究。采用Kaplan Meier法确定生存水平，为确定影响患者生存的因素，使用Log - rank检验进行单因素分析。
在2013年11月至12月对这些患者进行随访时，估计这些患者1年、2年、3年、4年和5年的生存率分别为0.77%、0.65%、0.52%、0.44%、0.27%，生存中位数为19个月，平均生存时间为24.49个月。基于秩对数检验和FDR方法，确定一些变量如分期（p<0.001）、放疗（p<0.005）以及在辅助化疗前接受手术（p<0.001）是影响生存概率的有效因素。
与发达国家相比，本文所涉及患者的寿命较短，这可能是由于就诊延迟或诊断延误以及治疗设施不足所致。如此一来，一些措施如早期诊断和筛查方法可能对提高患者生存率有效。
